Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron

European Journal of Haematology

Volumn 89, Issue 1, 2012, Pages 87-93

  Ghoti, Hussam ^a   Rachmilewitz, Eliezer A ^a   Simon Lopez, Ramon ^b   Gaber, Raed ^a   Katzir, Zeev ^a   Konen, Eli ^c   Kushnir, Tamar ^c   Girelli, Domenico ^c   Campostrini, Natascia ^d   Fibach, Eitan ^e   Goitein, Orly ^c  

^a WOLFSON MEDICAL CENTER   (Israel)

^b BECKMAN COULTER INC   (United States)

^c SHEBA MEDICAL CENTER   (Israel)

^d UNIVERSITY OF VERONA   (Italy)

^e HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Anemia; Erythropoietin; Ferritin; Iron; Iron overload; Long term hemodialysis

Indexed keywords

C REACTIVE PROTEIN; FERRIC HYDROXIDE SUCROSE; FERRITIN; HEMOGLOBIN; HEPCIDIN; IRON SACCHARATE; MALONALDEHYDE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FERRITIN BLOOD LEVEL; HEART LEFT VENTRICLE FUNCTION; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON OVERLOAD; LIPID PEROXIDATION; LIVER; LONG TERM CARE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PANCREAS; PRIORITY JOURNAL; SIDE EFFECT; SPLEEN; TRANSFERRIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ERYTHROPOIETIN; FEMALE; FERRITINS; HUMANS; IRON; IRON OVERLOAD; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIUM; PANCREAS; RENAL DIALYSIS; SPLEEN;

EID: 84862558474     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2012.01783.x     Document Type: Article

References (41)

1. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the dialysis patients' response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007;18:975-84.
2. Kapoian T, O'Mara NB, Singh AK, Moran J, Rizkala AR, Geronemus R, Kopelman RC, Dahl NV, Coyne DW. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 2008;19:372-9.
3. Kalantar-Zadeh K, Kalantar-Zadeh K, Lee G. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol 2006;1:S9-18.
4. Barnett MD, Gordon YB, Amess JA, Mollin DL. Measurement of ferritin in serum by radioimmunoassay. J Clin Pathol 1978;31:742-8.
5. Bird RP, Draper HH. Comparative studies on different methods of malonaldehyde determination. Methods Enzymol 1984;105:299-305.
6. Swinkels DW, Girelli D, Laarakkers C, Kroot J, Campostrini N, Kemna EH, Tjalsma H. Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry. PLoS ONE 2008;3:e2706.
7. Corbella M, Girelli G, Traglia M, et al. Serum Hepcidin by a mass-spectrometry based assay at population level. Results from the Val Borbera Study. Am J Hematol 2011; DOI: 10.1002/ajh.22083Abstract Book of the fourth congress of the International Bioiron Society:91.
8. Anderson LJ, Holden S, Davis B, et al.Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22:2171-9.
9. Westwood MA, Wonke B, Maceira AM, Prescott E, Walker JM, Porter JB, Pennell DJ. Left ventricular diastolic function compared with T2* cardiovascular magnetic resonance for early detection of myocardial iron overload in thalassemia major. J Magn Reson Imaging 2005;22:229-33.
10. Taccone-Gallucci M, Di Nucci G, Meloni C, Mariani G, Valeri M, Piazza A, Elia L, Torromeo C, Mandelli F, Casciani CU. Risk of iron overload and 'hemochromatosis allele(s)' in patients on maintenance hemodialysis. Am J Nephrol 1987;7:28-32.
11. Winchester JF. Management of iron overload in dialysis patients. Semin Nephrol 1986;6:22-6.
12. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996;50:1694-9.
13. Kalantar-Zadeh K, Stenvinkel P, Pillon L, Kopple JD. Inflammation and nutrition in renal insufficiency. Adv Ren Replace Ther 2003;10:155-69.
14. Ferrari P, Kulkarni H, Dheda S, Betti S, Harrison C, St Pierre TG, Olynyk JK. Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol 2011;6:77-83.
15. Chuang CL, Liu RS, Wei YH, Huang TP, Tarng DC. Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients. Nephrol Dial Transplant 2003;18:370-7.
16. Esposito BP, Breuer W, Slotki I, Cabantchik ZI. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest 2002;32 (Suppl 1):42-9.
17. Van Wyck D, Anderson J, Johnson K. Labile iron in parenteral iron formulations: a quantitative and comparative study. Nephrol Dial Transplant 2004;19:561-5.
18. Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med 2011;62:347-60.
19. Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, Umehara H, Ishikawa I. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood 2006;108:1381-7.
20. Bishu K, Agarwal R. Acute injury with intravenous iron and concerns regarding long-term safety. Clin J Am Soc Nephrol 2006;1 (Suppl 1):S19-23.
21. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-24.
22. Livrea MA, Tesoriere L, Pintaudi AM, Calabrese A, Maggio A, Freisleben HJ, D'Arpa D, D'Anna R, Bongiorno A. Oxidative stress and antioxidant status in beta-thalassemia major: iron overload and depletion of lipid-soluble antioxidants. Blood 1996;88:3608-14.
23. Amer J, Ghoti H, Rachmilewitz E, Koren A, Levin C, Fibach E. Red blood cells, platelets and polymorphonuclear neutrophils of patients with sickle cell disease exhibit oxidative stress that can be ameliorated by antioxidants. Br J Haematol 2006;132:108-13.
24. Ghoti H, Amer J, Winder A, Rachmilewitz E, Fibach E. Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome. Eur J Haematol 2007;79:463-7.
25. Shizukuda Y, Bolan CD, Nguyen TT, Botello G, Tripodi DJ, Yau YY, Waclawiw MA, Leitman SF, Rosing DR. Oxidative stress in asymptomatic subjects with hereditary hemochromatosis. Am J Hematol 2007;82:249-50.
26. Klemm A, Voigt C, Friedrich M, Funfstuck R, Sperschneider H, Jager EG, Stein G. Determination of erythrocyte antioxidant capacity in haemodialysis patients using electron paramagnetic resonance. Nephrol Dial Transplant 2001;16:2166-71.
27. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003;18:1272-80.
28. Pai AB, Conner T, McQuade CR, Olp J, Hicks P. Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose. Biometals 2011;24:603-13.
29. Kakhlon O, Cabantchik ZI. The labile iron pool: characterization, measurement, and participation in cellular processes(1). Free Radic Biol Med 2002;33:1037-46.
30. Fibach E, Rachmilewitz E. The role of oxidative stress in hemolytic anemia. Curr Mol Med 2008;8:609-19.
31. Wood JC. Magnetic resonance imaging measurement of iron overload. Curr Opin Hematol 2007;14:183-90.
32. Schwenzer NF, Machann J, Haap MM, et al.T2* relaxometry in liver, pancreas, and spleen in a healthy cohort of one hundred twenty-nine subjects-correlation with age, gender, and serum ferritin. Invest Radiol 2008;43:854-60.
33. Ghoti H, Goitein O, Koren A, Levin C, Kushnir T, Rachmilewitz E, Konen E. No evidence for myocardial iron overload and free iron species in multitransfused patients with sickle/beta-thalassaemia. Eur J Haematol 2009;84:59-63.
34. Konen E, Ghoti H, Goitein O, Winder A, Kushnir T, Eshet Y, Rachmilewitz E. No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique. Am J Hematol 2007;82:1013-6.
35. Ruiz-Jaramillo Mde L, Guizar-Mendoza JM, Amador-Licona N, Gutierrez-Navarro Mde J, Hernandez-Gonzalez MA, Dubey-Ortega LA, Solorio-Meza SE. Iron overload as cardiovascular risk factor in children and adolescents with renal disease. Nephrol Dial Transplant 2011;26:3268-73.
36. Gokal R, Millard PR, Weatherall DJ, Callender ST, Ledingham JG, Oliver DO. Iron metabolism in haemodialysis patients. A study of the management of iron therapy and overload. Q J Med 1979;48:369-91.
37. Canavese C, Bergamo D, Ciccone G, Longo F, Fop F, Thea A, Martina G, Piga A. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int 2004;65:1091-8.
38. Kovesdy CP, Kalantar-Zadeh K. Iron therapy in chronic kidney disease: current controversies. J Ren Care 2009;35 (Suppl 2):14-24.
39. KDOQ1 Clinical Practive Guidelines and Clinical Practice Recommendations for Anemia in chronic kidney disease. Am J Kidney Dis 2006;47(Suppl 3):S11-145.
40. Roger S. The CARI guidelines. Haematological targets. Iron Nephrol (Carlton) 2004;11:S217-29.
41. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005;16:3070-80.